LUNG Pulmonx Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1127537 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.2%
TTM net income YoY25.0%
TTM EPS YoY28.4%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—
Margins
Gross margin77.4%
Operating margin-44.4%
Net margin-47.9%
FCF margin-28.8%
EBITDA margin-43.4%
Returns
ROE-90.3%
ROA-34.2%
ROIC (approx.)-155.9%
Asset turnover0.71x
Leverage & solvency
Liabilities / assets69.0%
Debt / equity1.11x
Current ratio4.05x
Interest coverage-9.39x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-13.7%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $22.84M | $22.76M | $20.59M | $22.60M | $21.50M | $23.86M | $22.54M | $23.77M |
| Cost of revenue | $5.44M | $5.01M | $4.54M | $5.06M | $5.45M | $6.66M | $6.20M | $6.17M |
| Gross profit | $17.40M | $17.74M | $16.04M | $17.54M | $16.05M | $17.20M | $16.34M | $17.59M |
| R&D expense | $4.86M | $5.03M | $4.90M | $4.58M | $4.85M | $5.31M | $4.76M | $4.00M |
| SG&A expense | $20.02M | $21.77M | $24.10M | $22.86M | $25.60M | $26.70M | $26.15M | $27.01M |
| Operating income | -$7.49M | -$9.06M | -$12.96M | -$9.90M | -$14.39M | -$14.80M | -$14.56M | -$13.42M |
| Interest expense | $1.23M | $1.22M | $976,000 | $770,000 | $805,000 | $799,000 | $781,000 | $842,000 |
| Pretax income | -$8.24M | -$9.95M | -$13.51M | -$10.24M | -$13.83M | -$15.00M | -$14.31M | -$13.14M |
| Income tax | $151,000 | $133,000 | $149,000 | $186,000 | $128,000 | $177,000 | $135,000 | $38,000 |
| Net income | -$8.39M | -$10.08M | -$13.65M | -$10.43M | -$13.96M | -$15.17M | -$14.45M | -$13.18M |
| EBITDA | -$7.29M | -$8.86M | -$12.76M | -$9.60M | -$14.09M | -$14.50M | -$14.26M | -$13.32M |
| EPS (basic) | -0.19 | -0.24 | -0.33 | — | -0.34 | -0.38 | -0.36 | — |
| EPS (diluted) | -0.19 | -0.24 | -0.33 | — | -0.34 | -0.38 | -0.36 | — |
| Weighted avg. shares (diluted) | 43.18M | 42.47M | 41.90M | — | 40.94M | 40.43M | 39.95M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $52.69M | $55.84M | $61.57M | $69.75M | $76.55M | $75.47M | $74.56M | $71.16M |
| Receivables | $12.01M | $12.25M | $10.83M | $12.07M | $13.80M | $15.90M | $13.97M | $13.12M |
| Inventory | $15.44M | $16.39M | $16.31M | $15.85M | $16.25M | $16.18M | $16.81M | $16.91M |
| Current assets | $84.06M | $88.13M | $92.75M | $101.68M | $111.23M | $120.02M | $123.94M | $136.25M |
| PP&E, net | $1.76M | $1.89M | $2.06M | $2.22M | $2.44M | $2.66M | $2.83M | $2.91M |
| Goodwill | $2.33M | $2.33M | $2.33M | $2.33M | $2.33M | $2.33M | $2.33M | $2.33M |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $110.21M | $114.73M | $119.97M | $129.29M | $138.28M | $147.19M | $150.74M | $162.85M |
| Current liabilities | $20.74M | $20.41M | $18.91M | $20.06M | $22.88M | $22.45M | $24.95M | $24.44M |
| Short-term debt | $100,000 | $103,000 | $104,000 | $106,000 | $105,000 | $104,000 | $7.80M | $3.18M |
| Long-term debt | $37.71M | $37.43M | $37.21M | $36.99M | $37.02M | $37.01M | $29.39M | $34.00M |
| Total debt | $37.81M | $37.53M | $37.31M | $37.09M | $37.13M | $37.12M | $37.20M | $37.18M |
| Total liabilities | $76.01M | $75.54M | $74.20M | $75.17M | $78.25M | $78.10M | $73.07M | $77.04M |
| Shareholders' equity | $34.20M | $39.20M | $45.76M | $54.12M | $60.03M | $69.09M | $77.67M | $85.81M |
| Net debt | -$14.88M | -$18.31M | -$24.26M | -$32.66M | -$39.42M | -$38.35M | -$37.36M | -$33.98M |
| Shares outstanding | 43.55M | 42.95M | 42.24M | 41.67M | 41.25M | 40.74M | 40.25M | 39.79M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.18M | -$5.21M | -$10.10M | -$7.08M | -$8.16M | -$3.91M | -$13.22M | -$6.73M |
| Capital expenditure | $8,000 | $1,000 | $9,000 | $13,000 | $89,000 | $49,000 | $301,000 | $111,000 |
| Free cash flow | -$3.19M | -$5.21M | -$10.11M | -$7.10M | -$8.25M | -$3.96M | -$13.52M | -$6.84M |
| Investing cash flow | -$8,000 | -$1,000 | -$9,000 | -$13,000 | $8.71M | $5.47M | $16.31M | $14.07M |
| Financing cash flow | $161,000 | -$513,000 | $2.03M | $55,000 | $181,000 | -$67,000 | $664,000 | $62,000 |
| Depreciation & amortization | $200,000 | $200,000 | $200,000 | $300,000 | $300,000 | $300,000 | $300,000 | $100,000 |
| Stock-based compensation | $3.61M | $3.70M | $4.14M | $4.24M | $5.17M | $6.21M | $5.61M | $5.52M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.